Abstract
P. Andrew Allred, MS, PA-C, of Banner MD Anderson Cancer Center, considers data on managing newly diagnosed MM and CAR T-cell therapy in MM. Amy Pierre, MSN, ANP-BC, of MSKCC and Flatiron Health, reviews findings on telemedicine inequities and real-world data on axicabtagene ciloleucel. Meredith Beaton, MSN, RN, of UCHealth, evaluates data on FLT3-mutated AML and TKI discontinuation in CML. Pamela Lee, NP, MSN, of UCSF Medical Center, analyzes results of a new BiTE therapy in DLBCL and CAR T-cell therapy in MCL. Amber Koehler, PA-C, of Mayo Clinic Cancer Center, reviews combination therapies for CLL.
